Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27247258 | 1.00 | MEN1 (0.40) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL30920540 | 1.00 | MEN1 (0.40) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL27247282 | 1.00 | MEN1 (0.40) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL27247316 | 0.94 | MAPT (0.39) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL30920647 | 0.94 | MAPT (0.39) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL30920646 | 0.94 | MAPT (0.39) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL30920345 | 0.91 | KMT2A (0.40) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL27247846 | 0.91 | KMT2A (0.40) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL30920768 | 0.89 | NPC1 (0.43) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL30920800 | 0.89 | NPC1 (0.41) | MEN1KMT2AALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | MEN1 2882/4885KMT2A 3366/4885ALDH1A1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.